| abstract |
REFERS TO COMPOUNDS OF FORMULA (I), WHERE W IS A LINK, -C (= S) -, -S (O) (1-2) -, -C (= O) -, -O-, - C (R6) (R7) -, AMONG OTHERS; X IS -O-, -N (R5) - O -C (R6) (R7) -, WITH THE CONDITION THAT WHEN X IS -O- U IT IS NOT -O-, -S (O) (1-2 ) -, -C (= O) - O -C (= NR5) -; U IS -S (O) (1-2) -, -C (O) -, - O-, - (C (R6) (R7)) b-, AMONG OTHERS; R1, R2 AND R5 ARE INDEPENDENTLY, H, ALKYL, ALKENYL, AMONG OTHERS; R3 AND R4 ARE INDEPENDENTLY, H, ALKYL, CYCLOALKYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: 5-ETHYL CYCLOHEXIL-2-IMINO-3-METHYL-5 - ({3 - [(2-OXOETHYL) AMINO] CYCLOHEXYL} METHYL) -IMIDAZOL-4-ONA, 5-ETHYL CYCLOHEXIL-2-IMINO-3 -METIL-5 - ({3- (PYRROLIDIN) -CYCLOHEXYL} METHYL) -IMIDAZOL-4-ONA, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE INHIBITORS OF ASPARTILE PROTEASE, SO THEY ARE USEFUL IN THE TREATMENT OF CARDIOVASCULAR, COGNITIVE AND NEURODEGENERATIVE DISEASES |